H. Ralph  Snodgrass net worth and biography

H. Snodgrass Biography and Net Worth

Dr. Snodgrass co-founded VistaGen with Dr. Gordon Keller in 1998 and served as our Chief Executive Officer until August 2009. He has more than 20 years of experience in senior biotechnology management and is recognized as an expert in stem cell biology with more than 28 years' experience in the uses of stem cells as biological tools for research, drug discovery and development. Prior to founding VistaGen, Dr. Snodgrass served as a key member of the executive management team that led Progenitor, Inc., a biotechnology company focused on developmental biology, through its initial public offering, and was its Chief Scientific Officer and Executive Director. Dr. Snodgrass also has over 10 years of research experience as a professor at the Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill School of Medicine, and served as a member of the Institute for Immunology, Basel, Switzerland. He is a former Board Member of the Emerging Company Section of the Biotechnology Industry Organization (BIO), and a former member of the International Society Stem Cell Research Industry Committee. Dr. Snodgrass has published more than 50 scientific papers, is the inventor of more than 17 patents and a number of patent applications, and is or has been, the Principal Investigator on U.S. federal and private foundation sponsored research grants with budgets totaling more than $14.5 million. He received his Ph.D. in immunology from the University of Pennsylvania.

How do I contact H. Ralph Snodgrass?

The corporate mailing address for Dr. Snodgrass and other Vistagen Therapeutics executives is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. Vistagen Therapeutics can also be reached via phone at (650) 577-3600 and via email at [email protected]. Learn More on H. Ralph Snodgrass' contact information.

Has H. Ralph Snodgrass been buying or selling shares of Vistagen Therapeutics?

H. Ralph Snodgrass has not been actively trading shares of Vistagen Therapeutics during the past quarter. Learn More on H. Ralph Snodgrass' trading history.

Who are Vistagen Therapeutics' active insiders?

Vistagen Therapeutics' insider roster includes Jerrold Dotson (CFO), and H. Snodgrass (Insider). Learn More on Vistagen Therapeutics' active insiders.

Are insiders buying or selling shares of Vistagen Therapeutics?

During the last twelve months, Vistagen Therapeutics insiders bought shares 1 times. They purchased a total of 775,756 shares worth more than $17,958,751.40. The most recent insider tranaction occured on August, 7th when Major Shareholder Commodore Capital Lp bought 775,756 shares worth more than $17,958,751.40. Insiders at Vistagen Therapeutics own 1.0% of the company. Learn More about insider trades at Vistagen Therapeutics.

Information on this page was last updated on 8/7/2023.

H. Ralph Snodgrass Insider Trading History at Vistagen Therapeutics

See Full Table

H. Ralph Snodgrass Buying and Selling Activity at Vistagen Therapeutics

This chart shows H. Ralph Snodgrass's buying and selling at Vistagen Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vistagen Therapeutics Company Overview

Vistagen Therapeutics logo
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $4.70
Low: $4.55
High: $4.77

50 Day Range

MA: $4.77
Low: $3.92
High: $5.42

2 Week Range

Now: $4.70
Low: $1.62
High: $24.71

Volume

193,744 shs

Average Volume

278,775 shs

Market Capitalization

$126.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77